Lever Bio is a Turin, Italy-based biotechnology company focused on developing novel immuno-oncology therapies. It leverages metabolic and immune system reprogramming to overcome resistance to existing cancer treatments, particularly in solid tumors. The company advances programs through strategic in-licensing agreements and collaborations with leading research institutions. Lever Bio announced €4M in funding and intends to use the funds to further progress its assets through preclinical development. It plans to validate the therapeutic potential and positioning of its biologics in solid tumors. The company is led by its CEO and is focused on advancing novel biologics to improve patient outcomes.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

May 2025